Table 3.
Current human clinical trials for stem cell intervention in diabetes treatment
| Phase | Condition | Intervention | Status | Eligibility (age, gender) | Location (s) | NIH ClinicalTrials.gov study title with link |
|---|---|---|---|---|---|---|
| 1/2 | Type 2 diabetes | Procedure: Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs) | Recruiting | 18-80 years, both genders | Miami, FL, USA | Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivers in Patients with type II diabetes |
| Unknown | Diabetes mellitus (patients undergoing hematopoietic stem cell transplant) | Procedure: Assessment of therapy complications Other: laboratory biomarker analysis | Not yet recruiting | 18 years and older, both genders | Nashville, TN, USA | Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant |
| 4 | Type 2 diabetes | Drug: Saxagliptin Drug: placebo | Recruiting | 40 = 70 years, both genders | Washington, DC, USA | Effect of Saxagliptina on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early type 2 diabetes |
| 2 | Type 1 diabetes | Procedure: Immunosuppression and stem cell transplantation | Recruiting | 8-35 years, both genders | Nanjing, Jiangsu, China | Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset type 1 diabetes |
| 2 | Type 1 diabetes | Device: Stem Cell Educator | Recruiting | 14-60 years, both genders | 1. Shijiazhuang, Hebei, China 2. Changsha, Hunan, China 3. Jinan, Shandong, China 4. Oviedo, Asturias, Spain | Stem Cell Educator Therapy in type 1 diabetes |
| 2 | Type 1 diabetes | Biological: Autologous mesenchymal stem cell transplantation | Recruiting | 18-40 years, both genders | Uppsala, Sweden | Mesenchymal Stem Cells to Intervene in the Development of type 1 diabetes: A Blinded Randomized Study |
| 1 | Type 2 diabetes | Biological: Umbilical cord mesenchymal stem cells Biological: Controlled suspension liquid | Recruiting | 20-60 years, both genders | Beijing, China | Mesenchymal Stem Cells to Treat type 2 diabetes (UC-MSCs) |
| 1/2 | Diabetes mellitus, insulin dependent | Biological: Intravenous Mesenchymal stem cell infusion | Recruiting | 12-35 years, both genders | Ribeirão Preto, São Paulo, Brazil | Safety and Efficacy Of Mesenchymal Stem Cells in Newly-diagnosed Type 1 diabetic Patients |
| 2/3 | Type 1 diabetes | Biological: Autologous transplantation | Recruiting | 10-40 years, both genders | Chongqing, China | Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients with Onset of type 1 diabetes |
| 1/2 | Diabetes mellitus | Other: Intra thecal transplantation of autologous mono nuclear cells | Recruiting | 18-55 years, both genders | Pune, Maharashtra, India | Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Diabetes Mellitus (BMACD) |
| 1/2 | Type 2 diabetes | Other: Bone Marrow Mononuclear Cell Transplantation | Recruiting | 30-70 years, both genders | Beijing, China | Autologous Bone Marrow Mononuclear Cell Transplantation in Treating type 2 diabetes Mellitus |
| 1/2 | Type 1 diabetes | Device: Stem Cell Educator | Recruiting | 6-14 years, both genders | Changsha, Hunan, China | Reversal of type 1 diabetes in Children by Stem Cell Educator Therapy |
| 1 | Type 1 diabetes | Genetic: Stem Cell Educator Therapy | Not yet recruiting | 18 years and older, both genders | Hackensack, New Jersey, USA | A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes |
a
Saxagliptin is an FDA approved DPP-4 inhibitor prescription medicine DPP-4 inhibitors have been shown to increase Endothelial Progenitor Cells in patients with type 2 diabetes.
(ClinicalTrials.gov A service of the U.S. National Institutes of Health. https://clinicaltrials.gov/).